iTeos Therapeutics/$ITOS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About iTeos Therapeutics
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
Ticker
$ITOS
Sector
Health
Primary listing
Employees
173
Headquarters
Website
ITOS Metrics
BasicAdvanced
$448M
-
-$4.68
1.49
-
Price and volume
Market cap
$448M
Beta
1.49
52-week high
$18.13
52-week low
$4.80
Average daily volume
1.3M
Financial strength
Current ratio
7.528
Quick ratio
7.371
Long term debt to equity
0.731
Total debt to equity
1.038
Profitability
EBITDA (TTM)
-202.05
Effective tax rate (TTM)
-6.51%
Management effectiveness
Return on assets (TTM)
-18.49%
Return on equity (TTM)
-34.97%
Valuation
Price to book
0.79
Price to tangible book (TTM)
0.79
Price to free cash flow (TTM)
-4.035
Free cash flow yield (TTM)
-24.79%
Free cash flow per share (TTM)
-2.511
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
58.78%
3-year earnings per share growth (CAGR)
-17.78%
What the Analysts think about ITOS
Analyst ratings (Buy, Hold, Sell) for iTeos Therapeutics stock.
ITOS Financial Performance
Revenues and expenses
ITOS Earnings Performance
Company profitability
ITOS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for iTeos Therapeutics stock?
iTeos Therapeutics (ITOS) has a market cap of $448M as of August 08, 2025.
What is the P/E ratio for iTeos Therapeutics stock?
The price to earnings (P/E) ratio for iTeos Therapeutics (ITOS) stock is 0 as of August 08, 2025.
Does iTeos Therapeutics stock pay dividends?
No, iTeos Therapeutics (ITOS) stock does not pay dividends to its shareholders as of August 08, 2025.
When is the next iTeos Therapeutics dividend payment date?
iTeos Therapeutics (ITOS) stock does not pay dividends to its shareholders.
What is the beta indicator for iTeos Therapeutics?
iTeos Therapeutics (ITOS) has a beta rating of 1.49. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.